Abstracts tagged "Depression and psoriatic arthritis"

Abstract Number: 1598 • 2018 ACR/ARHP Annual Meeting
Depression and Anxiety Reduce Probability of Achieving a State of Minimal Disease Activity in Patients with Psoriatic Arthritis
Antonio Wong Lam¹, Justine Y. Ye², Dafna D Gladman¹ and Vinod Chandran², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Depression and/or anxiety are comorbidities associated with psoriatic arthritis (PsA) that may affect treatment response. We aimed to determine whether the presence of depression/anxiety…
Abstract Number: 2528 • 2017 ACR/ARHP Annual Meeting
Prevalence of Depression and Attention Deficit Hyperactivity Disorder in Female Patients at a Combined Psoriasis-Psoriatic Arthritis Center
Soumya M. Reddy¹, Rebecca Haberman², Eileen Lydon³, Andrea L. Neimann⁴, Malavika Attur³, Mark Butler⁵, Tanya M. Spruill⁵ and Jose U. Scher⁶, ¹Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, ²Department of Medicine (*contributed equally), New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Dermatology, New York University School of Medicine, New York, NY, ⁵Department of Population Health, New York University School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis affecting multiple clinical domains. Untreated, PsA has the potential for significant morbidity and disability. Psychiatric disorders…
Abstract Number: 1701 • 2016 ACR/ARHP Annual Meeting
The Presence of Depression Might be an Important Determinant of Achieving Minimal Disease Activity State in Psoriatic Arthritis
Agnes Szentpetery¹, Natsumi Ikumi¹, Brian Kirby² and Oliver FitzGerald³, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Depression and anxiety are well known comorbidities in psoriasis (PsO) and psoriatic arthritis (PsA) with higher prevalence in PsA. Patients with PsA have…
Abstract Number: 1375 • 2012 ACR/ARHP Annual Meeting
Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors
Emily McDonough¹, Arane Thavaneswaran², Adele Carty³, Sutharshini Shanmugarajah², Renise Ayearst⁴, Lihi Eder⁴, Vinod Chandran⁵, Cheryl Rosen⁶ and Dafna D. Gladman⁷, ¹Medicine, University of Toronto, Ontario, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁶Division of Dermatology, University of Toronto, Toronto western Hospital, Toronto, ON, Canada, ⁷Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) affects approximately 30% of patients with psoriasis and has the potential to cause severe joint damage. Research into the prevalence of…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.